DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree
KING OF PRUSSIA, PA and LONDON, UK (PRWEB) March 27, 2015 -- DrugDev announced company founder and current President of DrugDev SiteStart Melissa (Liss) Easy was named to the 2015 Philadelphia Business Journal 40 Under 40.
The 40 Under 40 list spotlights 40 dynamic, up-and-coming leaders less than 40 years of age for their professional accomplishments and community involvement. Winners are honored at an awards program in May, and profiled in a special supplement of the Philadelphia Business Journal.
Lyn Kremer, Publisher of the Philadelphia Business Journal, said, “Liss Easy exemplifies the kind of forward-thinking entrepreneur who transforms their industry. We hope Liss and her colleagues on this year’s honoree list will inspire others to innovate and drive continued growth in our local, national and global economy.”
Liss founded DrugDev because she saw major inefficiencies in the process of matching clinical trial investigators to pharma protocols. Her mission is to bring sponsors and investigators closer together by focusing on the needs of the doctors and providing them with better technology-driven solutions, service, and more open communication.
DrugDev started with a network of cardiologists, and has since grown through referral and invitation into the world’s largest opted-in investigator network and data sharing platform, today reaching more than 80,000 active investigators in 115 countries who are actively seeking new clinical trial opportunities. DrugDev enables sponsors, CROs and sites to leverage modern technologies to do more trials together.
DrugDev President and CEO Ibraheem Mahmood said, “Liss is guided by a steadfast belief that technology can build and strengthen relationships within the pharmaceutical industry and improve clinical research with the goal of bringing many more new drugs to patients. She is an extraordinary example of achievement in this new phase of our industry and is an amazing role model for her peers, and I congratulate her on this tremendous honor.”
Liss Easy said, “I’m very grateful and honored to be among these remarkable honorees, and feel much of the credit for this recognition should go to my colleagues at DrugDev who come to work every day with a passion to improve people’s lives by improving the clinical trial process.”
About DrugDev
DrugDev is an innovative technology company which provides cloud-based solutions to help sponsors, CROs and investigators do more clinical trials together. Built around the largest global network of active opted-in investigators, DrugDev’s unified solutions suite optimizes site selection and startup, investigator payments and clinical operations. DrugDev also serves as the trusted third-party host of the revolutionary Investigator Databank collaboration and powers the TransCelerate Investigator Registry. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs rely on DrugDev technology to do more trials at drugdev.com.
Brenda Nashawaty, DrugDev, http://www.drugdev.com, +1 617-688-3253, [email protected]
Share this article